Shopping Cart 0
Cart Subtotal
AED 0

Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2019

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020

Details

Microscopic Polyangiitis (MPA)-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis (MPA)-Pipeline Review, H1 2019, provides an overview of the Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline landscape.

Microscopic polyangiitis (MPA) is an uncommon disease. It is the result of blood vessel inflammation which can damage organ systems. The area most commonly affected by MPA includes the kidneys, lung, nerves, skin and joints. Symptoms include shortness of breath or cough, fever, loss of appetite, rashes, muscle and/or joint pain. Treatment includes immunosuppressive medications.

Microscopic Polyangiitis (MPA)-Therapeutics DevelopmentPipeline Overview Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2019

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Microscopic Polyangiitis (MPA)-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 2, 1, 1 and 1 respectively.

Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA) (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Microscopic Polyangiitis (MPA)-Overview

Microscopic Polyangiitis (MPA)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Microscopic Polyangiitis (MPA)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Microscopic Polyangiitis (MPA)-Companies Involved in Therapeutics Development

Celltrion Inc

ChemoCentryx Inc

InflaRx NV

Teijin Pharma Ltd

Microscopic Polyangiitis (MPA)-Drug Profiles

avacopan-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Microscopic Polyangiitis (MPA)-Dormant Projects

Microscopic Polyangiitis (MPA)-Discontinued Products

Microscopic Polyangiitis (MPA)-Product Development Milestones

Featured News & Press Releases

May 18, 2017: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Blitzima (rituximab)

Dec 15, 2016: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Truxima

Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis

Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2019 6

Number of Products under Development by Companies, H1 2019 7

Number of Products by Top 10 Targets, H1 2019 9

Number of Products by Stage and Targets, H1 2019 9

Number of Products by Mechanism of Actions, H1 2019 11

Number of Products by Stage and Mechanism of Actions, H1 2019 11

Number of Products by Routes of Administration, H1 2019 13

Number of Products by Stage and Routes of Administration, H1 2019 13

Number of Products by Molecule Types, H1 2019 15

Number of Products by Stage and Molecule Types, H1 2019 15


List Of Table

List of Tables

Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Microscopic Polyangiitis (MPA)-Pipeline by Celltrion Inc, H1 2019

Microscopic Polyangiitis (MPA)-Pipeline by ChemoCentryx Inc, H1 2019

Microscopic Polyangiitis (MPA)-Pipeline by InflaRx NV, H1 2019

Microscopic Polyangiitis (MPA)-Pipeline by Teijin Pharma Ltd, H1 2019

Microscopic Polyangiitis (MPA)-Dormant Projects, H1 2019

Microscopic Polyangiitis (MPA)-Discontinued Products, H1 2019

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Microscopic Polyangiitis (MPA) Therapeutic Products under Development, Key Players in Microscopic Polyangiitis (MPA) Therapeutics, Microscopic Polyangiitis (MPA) Pipeline Overview, Microscopic Polyangiitis (MPA) Pipeline, Microscopic Polyangiitis (MPA) Pipeline Assessment


Companies

Celltrion Inc

ChemoCentryx Inc

InflaRx NV

Teijin Pharma Ltd

Company Profile

Company Profile Title

Microscopic Polyangiitis (MPA)-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis (MPA)-Pipeline Review, H1 2019, provides an overview of the Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline landscape.

Microscopic polyangiitis (MPA) is an uncommon disease. It is the result of blood vessel inflammation which can damage organ systems. The area most commonly affected by MPA includes the kidneys, lung, nerves, skin and joints. Symptoms include shortness of breath or cough, fever, loss of appetite, rashes, muscle and/or joint pain. Treatment includes immunosuppressive medications.

Microscopic Polyangiitis (MPA)-Therapeutics DevelopmentPipeline Overview Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2019

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Microscopic Polyangiitis (MPA)-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 2, 1, 1 and 1 respectively.

Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA) (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Microscopic Polyangiitis (MPA)-Overview

Microscopic Polyangiitis (MPA)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Microscopic Polyangiitis (MPA)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Microscopic Polyangiitis (MPA)-Companies Involved in Therapeutics Development

Celltrion Inc

ChemoCentryx Inc

InflaRx NV

Teijin Pharma Ltd

Microscopic Polyangiitis (MPA)-Drug Profiles

avacopan-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Microscopic Polyangiitis (MPA)-Dormant Projects

Microscopic Polyangiitis (MPA)-Discontinued Products

Microscopic Polyangiitis (MPA)-Product Development Milestones

Featured News & Press Releases

May 18, 2017: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Blitzima (rituximab)

Dec 15, 2016: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Truxima

Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis

Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2019 6

Number of Products under Development by Companies, H1 2019 7

Number of Products by Top 10 Targets, H1 2019 9

Number of Products by Stage and Targets, H1 2019 9

Number of Products by Mechanism of Actions, H1 2019 11

Number of Products by Stage and Mechanism of Actions, H1 2019 11

Number of Products by Routes of Administration, H1 2019 13

Number of Products by Stage and Routes of Administration, H1 2019 13

Number of Products by Molecule Types, H1 2019 15

Number of Products by Stage and Molecule Types, H1 2019 15


List Of Table

List of Tables

Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Microscopic Polyangiitis (MPA)-Pipeline by Celltrion Inc, H1 2019

Microscopic Polyangiitis (MPA)-Pipeline by ChemoCentryx Inc, H1 2019

Microscopic Polyangiitis (MPA)-Pipeline by InflaRx NV, H1 2019

Microscopic Polyangiitis (MPA)-Pipeline by Teijin Pharma Ltd, H1 2019

Microscopic Polyangiitis (MPA)-Dormant Projects, H1 2019

Microscopic Polyangiitis (MPA)-Discontinued Products, H1 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Microscopic Polyangiitis (MPA) Therapeutic Products under Development, Key Players in Microscopic Polyangiitis (MPA) Therapeutics, Microscopic Polyangiitis (MPA) Pipeline Overview, Microscopic Polyangiitis (MPA) Pipeline, Microscopic Polyangiitis (MPA) Pipeline Assessment


Companies

Celltrion Inc

ChemoCentryx Inc

InflaRx NV

Teijin Pharma Ltd